RxDoctor Payments DataLook up a doctor →

Dhiman Basu, MD

Rheumatology · Colleyville, TXNPI 1336266964

Payments from drug & device makers

$6,206,168in general payments, 2019–2025

Across 5,032 payments — averaging $1233.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1M
  • GSK$957K
  • Novartis$883K
  • Eli Lilly$738K
  • Amgen$547K
  • AstraZeneca$309K
  • plus $1.8M from 54 others
$7,006in research payments, 2019–2025

Across 6 payments — averaging $1167.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie546$1,008,241
GSK407$957,370
Novartis181$883,107
Eli Lilly32$738,460
Amgen(2 entities)853$547,424
AstraZeneca(2 entities)409$308,588
Janssen Research & Development, LLC27$174,997
ANI Pharmaceuticals, Inc.215$125,930
Mallinckrodt Hospital Products Inc.204$118,068
Aurinia Pharma U.S., Inc.237$116,518
UCB SA13$115,656
Lilly USA, LLC300$112,086
E.r. Squibb & Sons, L.L.C.88$96,509
Mallinckrodt Enterprises LLC136$95,535
UCB, Inc.254$92,392
Janssen Scientific Affairs, LLC94$83,124
Johnson & Johnson(2 entities)221$81,463
Pfizer150$79,333
Bristol Myers Squibb57$75,671
Sanofi122$74,308
Astrazeneca UK Limited3$58,379
Astrazeneca AB1$55,447
Sun Pharmaceutical Industries Inc.36$44,701
Kyowa Kirin, Inc.95$36,477
Daiichi Sankyo Company LTD9$31,747
Daiichi Sankyo Inc.19$22,903
Vertex1$16,450
Sandoz11$10,889
Sanofi US Services Inc.22$9,646
Swedish Orphan Biovitrum AB2$8,340
Genentech USA, Inc.57$6,347
Gilead18$5,253
Regeneron Healthcare Solutions, Inc.13$3,716
Octapharma USA, Inc.19$3,105
Regeneron2$3,030
Mylan Inc.3$1,098
Sanofi-aventis U.S. LLC8$623
Radius Health, Inc.19$363
Organon31$358
Boehringer Ingelheim17$332
Genentech, Inc.3$325
Arbor Pharmaceuticals, Inc.22$300
Sobi, Inc7$253
Antares Pharma, Inc.10$174
Alnylam Pharmaceuticals Inc.5$103
Invivyd Inc4$102
Tersera Therapeutics LLC5$96
Biogen1$92
Kiniksa Pharmaceuticals International, PLC5$91
Takeda Pharmaceuticals U.S.A., Inc.4$77
Hikma Pharmaceuticals USA4$60
Ultragenyx Pharmaceutical Inc.3$53
Pacira Pharmaceuticals Incorporated2$53
Zyla Life Sciences, Inc.3$50
Fresenius Kabi USA, LLC3$48
Bioventus LLC3$48
Kiniksa Pharmaceuticals, Ltd.2$43
Pacira Therapeutics, Inc.2$30
Azurity Pharmaceuticals, Inc.2$30
Medexus Pharma, Inc.2$28

How this compares

$6,206,168 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas →

Medicare billing

Part B allowed, 2024
$1,456,333
Medicare patients
275
Services billed
105,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Colleyville

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →